Abstract
•
COVID-19 can present with delayed onset of symptoms in patients with lymphoma receiving rituximab-based chemoimmunotherapy. •
Despite delayed onset of symptoms with prolonged asymptomatic period, outcomes can be particularly severe, including respiratory failure, thrombotic complications, and death.
Keywords: COVID-19; Chemotherapy; Rituximab.
All Keywords
【저자키워드】 COVID-19, rituximab, Chemotherapy, 【초록키워드】 Respiratory failure, Thrombotic complications, outcome, rituximab, Asymptomatic, lymphoma, Patient, death, receiving, onset of symptom, 【제목키워드】 respiratory, Chemoimmunotherapy, failure, Delayed,
【저자키워드】 COVID-19, rituximab, Chemotherapy, 【초록키워드】 Respiratory failure, Thrombotic complications, outcome, rituximab, Asymptomatic, lymphoma, Patient, death, receiving, onset of symptom, 【제목키워드】 respiratory, Chemoimmunotherapy, failure, Delayed,
{{{ 추상적인 }}}
•
COVID-19는 리툭시맙 기반 화학면역요법을 받는 림프종 환자에서 지연된 증상 발병으로 나타날 수 있습니다. •
장기간의 무증상 기간과 함께 증상의 발병 지연에도 불구하고 호흡 부전, 혈전 합병증 및 사망을 포함하여 결과가 특히 심각할 수 있습니다.
{{ 키워드: }} 코로나19; 화학 요법; 리툭시맙.